Using novel cell penetra0ng Phylomer pep0des to access intracellular targets with biologics

Paul Wa'

Director and Chief Scien5fic Advisor

BREAK THROUGH PEPTIDE THERAPEUTICS

Disclaimer

The purpose of the presenta5on is to provide an update of the business of Phylogica Limited (ASX:PYC) ['Phylogica']. These slides have been prepared as a presenta5on aid only and the informa5on they contain may require further explana5on and/or clarifica5on. Accordingly, these slides and the informa5on they contain should be read in conjunc5on with past and future announcements made by Phylogica and should not be relied upon as an independent source of informa5on. Please contact Phylogica and/or refer to the Company's website for further informa5on.

The views expressed in this presenta5on contain informa5on derived from publicly available sources that have not been independently verified. No representa5on or warranty is made as to the accuracy, completeness or reliability of the informa5on.

Any forward looking statements in this presenta5on have been prepared on the basis of a number of assump5ons which may prove incorrect and the current inten5ons, plans, expecta5ons and beliefs about future events are subject to risks, uncertain5es and other factors, many of which are outside Phylogica's control.

Important factors that could cause actual results to differ materially from assump5ons or expecta5ons expressed or implied in this presenta5on include known and unknown risks. Because actual results could differ materially to assump5ons made and Phylogica's current inten5ons, plans, expecta5ons and beliefs about the future, you are urged to view all forward looking statements contained in this presenta5on with cau5on.

This presenta5on should not be relied on as a recommenda5on or forecast by Phylogica. Nothing in this presenta5on should be construed as either an offer to sell or a solicita5on of an offer to buy or sell shares in any jurisdic5on.

2

Phylogica: unique capabili0es for intracellular discovery and delivery of biologics drugs Poten0al to expand the druggable intracellular landscape by >10-fold with Phylomer

Func%onal Penetra%ng Pep%des (FPP) - Phylogica's proprietary cell penetra0ng pep0des.

s 3

Table of Contents

  • Company and Technology Overview

  • FPP Delivery PlaYorm

  • Oncology Programs - Myc, Stat5, YB1

  • Collabora5on Opportuni5es and Summary

4 4

Phylogica Limited published this content on 24 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 24 January 2017 03:25:01 UTC.

Original documenthttp://phylogica.com/media/articles/Investors---ASX-Announcements/20170124-Investor-Presentation---Biotech-Showcase---San-Francisco-1658/PhylogicaBiotechShowcaseSanFranciscoJanuary102017.pdf

Public permalinkhttp://www.publicnow.com/view/2A674E8C09368A06227401E55FD29A0B65625B13